Neonatal screening for congenital cytomegalovirus infection in Tehran, Iran, using Guthrie cards

Samileh Noorbakhsh1, Mohammad Farhadi2, Faezeh Haghghi3, Sara Minaeian1, Morteza Haghghi Hasanabad1*

1Pediatric Infectious Diseases Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
2Head and Neck Research Center, Iran University of Medical Sciences, Tehran, Iran
3Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

Received: February 2020, Accepted: April 2020

ABSTRACT

Background and Objectives: Cytomegalovirus (CMV) constitutes the most common viral cause of congenital infections in newborns worldwide. There are a significant number of asymptomatic newborns with congenital CMV infection in Iran, which may develop long-term sequelae of infection. Unfortunately, limited data exists from Iran on the rate of congenital CMV infection among neonates. The current study was aimed to investigate the prevalence of congenital CMV infection among Iranian neonates by testing Guthrie cards.

Materials and Methods: Guthrie cards were collected from infants within 2 weeks of life, and total DNA was extracted from samples by thermal shock and evaluated for CMV DNA using nested-PCR assay. CMV infection in newborns was confirmed through a commercial CMV PCR kit. Infected infants underwent further evaluation at the hospital.

Results: CMV infection was identified in four of 1174 infants (0.34%) which is approximately 3 cases per 1000 live births. Infected infants were asymptomatic at birth and had a normal hearing status similar to other children. There were no factors in relation with CMV infection among newborns.

Conclusion: According to the results of this study, infected infants with congenital CMV infection could identify at early stage by testing Guthrie cards (within 21 days of life). Furthermore, since there is a lack of CMV knowledge in our population, educating and effective counseling by obstetricians/ gynecologists to the pregnant women are recommended.

Keywords: Screening; Congenital cytomegalovirus infection; Guthrie card

INTRODUCTION

Cytomegalovirus (CMV) is a member of the Herpesvirus family, and constitutes the most common viral cause of congenital infections varying from asymptomatic state to fatal disease form in newborns (1). Approximately between 2 to 22 newborns per 1000 live births are congenitally infected with CMV, depending on variety of socioeconomic backgrounds and ethnic groups of different populations in the world (2).

Although most children with congenital CMV (cCMV) infection are normal or asymptomatic, however about 2% of asymptomatic infants and about half of the infants with CMV symptoms at birth (5-10% of total infected infants) will develop long term sequelae because of the infection (3). In other words, the lack of neonatal CMV screening program leads to identification of merely a small proportion of children with clinical symptoms suspicious to cCMV.
Based on recent investigations, diagnosis of infants with cCMV infection at early stages, when associated with useful interventions, could prevent from the late onset sequelae of infection such as speech disabilities in children with bilateral hearing loss (5). However, prenatal CMV infection in neonates is commonly occurred after birth and accurate diagnosis of cCMV is only possible within the first three weeks of infants’ life (6).

In the last decade, traditional time-consuming detection methods of cCMV infection like culture assay have been replaced with fast-sensitive molecular tests such as PCR assays. Additionally, a great deal of studies has addressed the diagnostic feasibility of dried blood spots (DBS) on Guthrie cards by testing for CMV DNA in the light of its reliable sensitivity and specificity (7, 8). Unfortunately, limited data exists on cCMV infection rate among Iranian neonates in which the frequency of cCMV infections are mostly reported based on serological evaluation of neonates.

The aim of this multi-center study was to investigate the prevalence of cCMV infection in the six cities of Tehran province, Iran, by testing infants’ Guthrie cards.

MATERIALS AND METHODS

Population study. This prospective study was carried out at the seven university affiliated healthcare centers in the western regions of Tehran province from July 1 to August 31, 2017. These centers serve as the main referral units for neonatal screening of metabolic disorders in province, which approximately cover more than 70,000 newborns per year and present a wide range of cares and facilities to about 5 million people living in six cities in these regions.

Ethical committee of Iran University of Medical Sciences approved this project (ethical code: IR.IUMS.REC.1394.25708) and written informed consent was signed by parents of all study participants. Moreover, educational brochures with data on CMV transmission, infection and prevention were distributed among all parents. The main characteristics details and clinical data of infants were collected by questionnaire or from medical records and their maternal data were obtained from “electronic health documents of Iranian families” (SIB System). Hospitalized infants in neonatal intensive care unit (NICU) were excluded from the study.

Sampling. After completion of metabolic tests in the central reference laboratory, 2 circles from each Guthrie card (Whatman 903, LOT 82509/112) were cut out by sterile scissors, stored in sealed plastic bags containing desiccant (9) and transported to the research laboratory at institute of immunology and infectious diseases (Hazrate-Rasool hospital), for CMV PCR test.

DNA extraction. Total DNAs were extracted from DBS samples in triplicate by using thermal shock (modified protocol) as described by de Vries et al. (10). In brief, a disk of each DBS (3 mm in diameter) was punched into a 1.5 ml tube containing 35 μl Minimal Essential Medium (MEM, Sigma Aldrich Co.) and incubated at 4°C overnight. Samples were heated in thermal cycler (Labcycler Basic, Goettingen, Germany), according to the following program: 55°C for 60 min, 100°C for 7 min, 4°C for 2 min, and further centrifuged at 3300 ×g for 15 min. The supernatant (20-25 μl) was transferred to another tube and frozen at -80°C for at least one night.

CMV DNA amplification. An in-house nested PCR assay was developed with specific primers for amplification of a conserved region in the gB gene (glycoprotein B) of CMV. Briefly, using 7 μl of DNA template in a final volume of 25 μl PCR mixture consisted of 12.5 μl PCR Master Mix, 2 μl external primers, 3.5 μl sterile water and over conditions as follow: 94°C 2 min; [94°C 30 s, 58°C 45 s, 72°C 60 s] × 35 cycles; 72°C 5 min, a 450 bp fragment was amplified in the primary PCR. Subsequently, using 1 μl of first amplification product as template for the secondary PCR and under the same conditions as mentioned above, with except for primers (internal) and annealing temperature (55°C), a 220 bp fragment was amplified in the second round. Finally, PCR products were separated through electrophoresis on 2% agarose gels (Kowsar molecular Co. Iran) and visualized under the UV light. The sequences of oligonucleotides illustrated in Table 1.

Quality Control. A blank Whatman card was punched before testing each sample to prevent cross contamination between DBSs. CMV PCR assay was set up using triplicate testing of DBS spotted with dif-
Table 1. The Sequence of Primers used for nested PCR assay

| PCR          | Primers      | Sequence (5’-3’)                          | Product Size |
|--------------|--------------|-------------------------------------------|--------------|
| Conventional | Outer-1      | ACAGACACAAACACGACACC                      | 450 bp       |
| n-PCR        | Outer-2      | TAAAGTGACGACACGGTGGG                      | 220 bp       |
| (gB Gene)    | Inner-1      | ACACGCATACCTCAACACC                      | 110 bp       |
|              | Inner-2      | GGCCCATGGTCCAGAGCG                      |              |
| Internal Control | PC03  | ACACACTGTTCTACAGGC                      | 110 bp       |
| (β-globin Gene) | PC04  | CAACACTGCCAGCTCCACC                      |              |

In highlights, 673 were males and 501 were females, the mean birth weight of infants at birth time was 3088 gr. (SD = ± 352), preterm delivery was documented in 145 cases, and symptoms associated with cCMV infection (petechiae, jaundice and hearing loss) were observed in 168 newborns.

According to results of CMV PCR test, CMV DNA was found in DBS and urine samples of 4 infants (0.34%, Confidence Interval 95% (CI): 0.09-0.87), which approximately is equal to 3 cases per 1000 live births (1 per 294). In details, all four infants with cCMV infection (1 male and 3 female) were asymptomatic at birth and no symptoms or signs was observed in general examination. Their results of clinical and laboratory assessment revealed a normal condition similar to other children. Anti-CMV IgG antibody was found in the serum samples of all cases while anti-CMV IgM antibody was detected in only one infected infant.

In statistical analysis of data, no factor was found in association with neonatal CMV infection. The main characteristics data of infants by cCMV infection status demonstrated in Table 2.

**DISCUSSION**

While congenital CMV infection is known as a
public health priority in developed countries, context
is not clear in developing countries, like Iran (12).
The current study provides documented data for the
first time in Iran on congenital CMV infection rate
by testing infants’ DBS cards. According to our re-
sults, cCMV infection was observed in 4 of 1176 in-
fants who born in 6 cities of Tehran province, Iran
(0.34%).

Our finding in this study is consistent with previ-
ous report from Tehran in which 0.32% of neonates
(2 of 620) in a hospital were infected with CMV at
birth (13). Additionally, similar findings were report-
ed by two other studies with large sample sizes from
Iran in which 0.49% and 0.65% of newborns in Isfahan
and Gorgan cities (central and northern regions of
Iran) were infected with CMV, respectively (14, 15).

In comparison with developing countries with high
maternal CMV seroprevalence, the frequency of
cCMV infection that we found in the current study is
in agreement with recently reported rates of infection
from Brazil (0.6%) and China (0.7%), but in contrast
to one report from Turkey (1.9%) (16-18). Differences
in socioeconomic status and public health levels
as well as ethnicity variations within populations,
probably justify some of these reported differences
between studies (19).

All infected neonates with CMV were born as-
symptomatic in our study (A mild jaundice in one
case was observed). Consistently, it has been report-
ed by many studies from populations of countries
with high maternal CMV seroprevalence (20). One
reason may be due to existing of maternal antibod-
ies in neonates (anti-CMV IgG) which pass during
fetal periods from mother-to-child. Approximately
95% of neonates in our study were born from moth-
ers with anti-CMV IgG antibody in their serum. In
addition, many researchers previously shown that
anti-CMV IgG antibodies were found positive in the
serum samples of 85% to 100% of Iranian pregnant
women (21-26).

According to previous studies, more than 85% of
CMV infected infants will never develop the late
onset sequelae of infection. Additionally, it is indi-
cated by some reports that positive DBS cards may
potentially discriminate infants at higher risk for de-
veloping sequelae (27). In line with these reports, a
chorioretinitis was detected in one of four infected
infants in current study after 9 months of birth (data
not shown).

Currently, while an efficient vaccine for cCMV

Table 2. Analysis of demographic and clinical characteristics of infants by eCMV infection status

|                | CMV-Positive (%) | CMV-Negative (%) | P-Value |
|----------------|------------------|------------------|---------|
| Sex            |                  |                  |         |
| Male           | 1 (0.2)          | 672 (99.8)       | NS**    |
| Female         | 3 (0.6)          | 498 (99.4)       |         |
| Preterm birth (<37 weeks) |                  |                  |         |
| Yes            | 2 (1.3)          | 143 (98.7)       | NS      |
| No             | 2 (0.2)          | 1027 (99.8)      |         |
| Jaundice       |                  |                  |         |
| Yes            | 1 (0.8)          | 113 (99.2)       | NS      |
| No             | 3 (0.2)          | 1057 (99.8)      |         |
| Petechiae      |                  |                  |         |
| Yes            | 0 (0.0)          | 43 (100.0)       | NS      |
| No             | 4 (0.3)          | 1127 (99.7)      |         |
| Hearing loss*  |                  |                  |         |
| Yes            | 0 (0.0)          | 11 (100.0)       | NS      |
| No             | 4 (0.3)          | 1159 (99.7)      |         |
| Birth weight (mean ± SD) | 2975.0 (±206)    | 3201.7 (±499)    | NS      |
| Body length (mean ± SD) | 47.0 (±0.8)      | 49.0 (±3.0)      | NS      |
| Head circumference (mean ± SD) | 34.0 (±0.8)      | 35 (±2.0)        | NS      |

* Results of initial hearing screening test by OAE test
** Not Significant
infection is not available, risk of infection among populations can be reduced by developing prevention-based strategies like attention to simple hygiene practices such as routine hand washing (28). In this study, few parents have heard CMV or CMV associated sequelae before and awareness level about CMV precautionary actions was very low in our population.

At last, there were some limitations in this study. Firstly, number of infected infants was not sufficient for the accurately analysis of results and secondly, the study site was located in one province and results may not be generalizable to other regions of our country.

CONCLUSION

This survey revealed that congenital CMV infection in neonates is at least twice more prevalent than metabolic and endocrine disorders (1 in 950) which are currently included in the screening panel of neonatal diseases in Iran (29). Therefore, at least screening of symptomatic infants at birth seems to be necessary. In addition, educating the females at childbearing ages by healthcare-providers and effective counseling of pregnant women by obstetricians/gynecologists are needed. Moreover, further studies with larger sample sizes in different regions of our country are recommended.

ACKNOWLEDGEMENTS

This study is part of Ph.D. thesis that was supported by Iran University of Medical Sciences, Tehran, Iran (Grant no. 25708). The authors thank the help and efforts from the staffs of referral healthcare units and reference laboratory personnel in the coordination of sampling and specimen collection. The authors also thank the participants for their involvement in this project.

REFERENCES

1. Harrison G (2014). Cytomegalovirus. Feigin and Cherry’s textbook of pediatric infectious disease 7th ed Elsevier Saunders Philadelphia, PP.1969.
2. Atkinson C, Emery V, Griffiths P. Development of a novel single tube nested PCR for enhanced detection of cytomegalovirus DNA from dried blood spots. J Virol Methods 2014;196:40-44.
3. Demmller-Harrison GJ, Weisman LE (2018). Congenital cytomegalovirus infection: clinical features and diagnosis. In: UpToDate. Ed, Ted. W. Post. UpToDate in Waltham, MA.
4. McMullen BJ, Palasanthiran P, Jones CA, Hall BM, Robertson PW, Howard J, et al. Congenital cytomegalovirus—time to diagnosis, management and clinical sequelae in Australia: opportunities for earlier identification. Med J Aust 2011;194:625-629.
5. Buonsenso D, Serranti D, Gargiullo L, Ceccarelli M, Ranno O, Valentini P. Congenital cytomegalovirus infection: current strategies and future perspectives. Eur Rev Med Pharmacol Sci 2012;16:919-935.
6. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007;17:253-276.
7. Barbi M, Binda S, Primache V, Caroppo S, Dido P, Guidetti P, et al. Cytomegalovirus DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. J Clin Virol 2000;17:159-165.
8. Barbi M, Binda S, Caroppo S. Diagnosis of congenital CMV infection via dried blood spots. Rev Med Virol 2006;16:385-392.
9. Scanga L, Chaing S, Powell C, Aylsworth AS, Harrell LJ, Henshaw NG, et al. Diagnosis of human congenital cytomegalovirus infection by amplification of viral DNA from dried blood spots on perinatal cards. J Mol Diagn 2006;8:240-245.
10. de Vries JJ, Barbi M, Binda S, Claas EC (2012). Extraction of DNA from dried blood in the diagnosis of congenital CMV infection. In: Diagnosis of Sexually Transmitted Disease. Eds, MacKenzie CR, Henrich B. Springer. pp. 169-175.
11. Saiki RK, Gelfand DH, Stoffel S, Scharf S, Higuchi R, Horn GT, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-491.
12. Waters A, Jennings K, Fitzpatrick E, Coughlan S, Molloy EJ, De Gascun CF, et al. Incidence of congenital cytomegalovirus infection in Ireland: implications for screening and diagnosis. J Clin Virol 2014;59:156-160.
13. Fahimzad A, Afgeh SA, Eghbali E, Abdinia B, Shiva F, Rahbar M. Screening of congenital CMV infection in saliva of neonates by PCR: report of a pilot screening study in Iran. Clin Lab 2013;59:1171-1174.
14. Karimian P, Yaghini O, Nasr Azadani H, Mohammadizadeh M, Arabzadeh SAM, Adibi A, et al. Prevalence, characteristics, and one-year follow-up of congenital cytomegalovirus infection in Isfahan City, Iran. Interdiscip Perspect Infect Dis 2016; 2016:7812106.
15. Javid N, Cheraghali F, Moradi A, Kelishadi M, Tabarraei A. Newborn screening for congenital cytomegalovirus infection in Iran. Pediatr Infect Dis J 2016;35:1052.

16. Yamamoto AY, Castellucci R, Aragon DC, Mussi-Pinhata MM. Early high CMV seroprevalence in pregnant women from a population with a high rate of congenital infection. Epidemiol Infect 2013;141:2187-2191.

17. Wang S, Wang T, Zhang W, Liu X, Wang X, Wang H, et al. Cohort study on maternal cytomegalovirus seroprevalence and prevalence and clinical manifestations of congenital infection in China. Medicine 2017;96(5):e6007.

18. Sahiner F, Cekmez F, Cetinkaya M, Kaya G, Kalayci T, Gunes O, et al. Congenital cytomegalovirus infections and glycoprotein B genotypes in live-born infants: a prevalence study in Turkey. Infect Dis (Lond) 2015;47:465-471.

19. Vauloup-Fellous C, Ducroux A, Couloigner V, Marlin S, Picone O, Galimand J, et al. Evaluation of cytomegalovirus (CMV) DNA quantification in dried blood spots: retrospective study of CMV congenital infection. J Clin Microbiol 2007;45:3804-3806.

20. Li L, Zhao L, Li Y. Prevalence of congenital cytomegalovirus infection in Beijing. Chin J Neonatol 2012;27:5-9.

21. Siadati A, Noorbakhsh S, Ghazi F, Rimaz SH, Monavari MR. Cytomegalovirus infection in primiparous pregnant women and their neonates. Acta Med Iran 2002;40:136-139.

22. Erfanianahmadpoor M, Nasiri R, Vakili R, Hassannia T. Seroprevalence, transmission, and associated factors of specific antibodies against cytomegalovirus among pregnant women and their infants in a regional study. Saudi Med J 2014;35:360-364.

23. Arabzadeh SA, Mosavat SA, Eftekhari N. Seropidemiology of human cytomegalovirus in pregnant women and their neonates in kerman city during 2005. J Kerman Univ Med Sci 2005;14:279-288.

24. Monavari Seyed Hamidreza, Keyvani H, Kiasari Bahman Abedi, Mollaei H, Fazlalipour M, Vaziri MS, et al. Detection of Cytomegalovirus (CMV) antibodies or DNA sequences from ostensibly healthy Iranian mothers and their neonates. Int J Med Sci 2012;4:155-159.

25. Ziyaeyan M1, Alborzi A, Abbasiyan, Kalani M, Mora-vej A, Nasiri J, et al. Detection of HCMV DNA in placenta, amniotic fluid and fetuses of seropositive women by nested PCR. Eur J Pediatr 2007;166:723-726.

26. Sepahvand P, Makvandi M, Samarbazdeh A, Talaei-Zadeh A, Ranjbari N, Nisi N, et al. Human Cytomegalovirus DNA among women with breast cancer. Asian Pac J Cancer Prev 2019;20:2275-2279.

27. Göhring K, Dietz K, Hartleif S, Jahn G, Hamprecht K. Influence of different extraction methods and PCR techniques on the sensitivity of HCMV-DNA detection in dried blood spot (DBS) filter cards. J Clin Virol 2010;48:278-281.

28. Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 2005;5:70.

29. Sotoodeh Jahromi A, Jamshidi Makiani M, Farjam M, Madani A, Amirian M, Eshbal Eftekhri T, et al. Cytomegalovirus immunity in pregnancy in south of Iran. Am J Infect Dis 2010;6:8-12.